理解特应性湿疹预防与治疗的经济学证据
该文旨在向皮肤科医生介绍经济学方法,并基于截至2017年5月22日检索12个在线数据库的系统文献检索,汇总湿疹预防与治疗的经济学证据。共纳入78项研究(80篇论文),其中33项(42%)为经济学评价,12项(15%)为成本分析,6项(8%)为效用分析,26项(33%)为疾病成本研究,1项(1%)为可行性研究。结论认为,针对湿疹预防与治疗干预的经济学证据水平相比临床结局证据有限,提示临床医生与经济学家之间加强合作可能有益。
要点
- 共纳入78项研究(80篇论文),33项(42%)为经济学评价。
- 钙调神经磷酸酶抑制剂他克莫司、吡美莫司及屏障霜的经济学证据最多。
- 部分水解婴儿配方奶粉是评估最多的预防措施。
核心结论
- 当前针对湿疹预防与治疗干预的经济学证据水平相比临床结局证据有限,提示临床医生与经济学家之间加强合作可能有益。
研究设计与样本
- 系统文献检索,检索12个在线数据库,截至2017年5月22日,纳入报告疾病成本研究结果或评价湿疹预防或治疗干预的成本、效用或完整经济学评价的原始实证研究,由两名评价者独立评估纳入资格并提取数据,分歧由第三名评价者解决,制作证据表进行叙述性讨论,并评估经济学评价的报告质量。
主要发现
- 78项研究(80篇论文)符合纳入标准;33项(42%)为经济学评价,12项(15%)为成本分析,6项(8%)为效用分析,26项(33%)为疾病成本研究,1项(1%)为可行性研究。
- 钙调神经磷酸酶抑制剂他克莫司和吡美莫司以及屏障霜的经济学证据最多。
- 部分水解婴儿配方奶粉是评估最多的预防措施。
临床怎么用
- 作者认为,当前湿疹预防与治疗干预的经济学证据水平相比临床结局证据有限,提示临床医生与经济学家之间加强合作可能有益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atopic eczema is an inflammatory skin condition, with a similar impact on health-related quality of life as other chronic diseases. Increasing pressures on resources within the National Health Service increase the importance of having good economic evidence to inform their allocation. OBJECTIVES: To educate dermatologists about economic methods with reference to currently available economic evidence on eczema. METHODS: The role of different types of economic evidence is illustrated by evidence found in a systematic literature search conducted across 12 online databases up to 22 May 2017. Primary empirical studies either reporting the results of a cost-of-illness study or evaluating the cost, utility or full economic evaluation of interventions for preventing or treating eczema were included. Two reviewers independently assessed studies for eligibility and performed data abstraction, with disagreements resolved by a third reviewer. Evidence tables of results were produced for narrative discussion. The reporting quality of economic evaluations was assessed. RESULTS: Seventy-eight studies (described in 80 papers) were deemed eligible. Thirty-three (42%) were judged to be economic evaluations, 12 (15%) cost analyses, six (8%) utility analyses, 26 (33%) cost-of-illness studies and one a feasibility study (1%). The calcineurin inhibitors tacrolimus and pimecrolimus, as well as barrier creams, had the most economic evidence available. Partially hydrolysed infant formula was the most commonly evaluated prevention. CONCLUSIONS: The current level of economic evidence for interventions aimed at preventing and treating eczema is limited compared with that available for clinical outcomes, suggesting that greater collaboration between clinicians and economists might be beneficial.
引用
- Sach TH, McManus E, Levell NJ, et al. Understanding economic evidence for the prevention and treatment of atopic eczema. Br J Dermatol. 2019. PMID: 30693473. doi:10.1111/bjd.17696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。